On Sept. 2, 2020, Novavax announced the publication in The New England Journal of Medicine of Phase 1 data from its Phase 1/2 clinical trial of NVX-CoV2373, its COVID-19 vaccine candidate adjuvanted with Matrix-Mﾙ, in healthy adults 18-59 years of age.

The publication offered further detail on the previously announced results, in which NVX-CoV2373 demonstrated a reassuring safety and reactogenicity profile and induced robust antibody responses numerically superior to that seen in human convalescent sera.